Technical Analysis for SLRN - Acelyrin Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 50 DMA | Bearish | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| 20 DMA Support | Bullish | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Crossed Above 20 DMA | Bullish | -3.85% | |
| Crossed Above 50 DMA | Bullish | -3.85% | |
| MACD Bullish Signal Line Cross | Bullish | -3.85% | |
| Expansion Pivot Buy Setup | Bullish Swing Setup | -3.85% | |
| Pocket Pivot | Bullish Swing Setup | -3.85% | |
| Volume Surge | Other | -3.85% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 6 hours ago |
| 20 DMA Support | about 9 hours ago |
| 60 Minute Opening Range Breakdown | about 9 hours ago |
| Down 5% | about 9 hours ago |
| Fell Below 20 DMA | about 9 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/13/2024
Acelyrin Inc. Description
ACELYRIN, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Drugs Monoclonal Antibodies Uveitis Psoriatic Arthritis Hidradenitis Suppurativa Thyroid Eye Disease Chronic Urticaria Duligotuzumab
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 29.88 |
| 52 Week Low | 3.67 |
| Average Volume | 944,554 |
| 200-Day Moving Average | 7.11 |
| 50-Day Moving Average | 4.36 |
| 20-Day Moving Average | 4.24 |
| 10-Day Moving Average | 4.09 |
| Average True Range | 0.31 |
| RSI (14) | 48.98 |
| ADX | 14.76 |
| +DI | 24.08 |
| -DI | 19.76 |
| Chandelier Exit (Long, 3 ATRs) | 4.08 |
| Chandelier Exit (Short, 3 ATRs) | 4.59 |
| Upper Bollinger Bands | 4.75 |
| Lower Bollinger Band | 3.73 |
| Percent B (%b) | 0.5 |
| BandWidth | 24.02 |
| MACD Line | -0.11 |
| MACD Signal Line | -0.13 |
| MACD Histogram | 0.0234 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.59 | ||||
| Resistance 3 (R3) | 4.60 | 4.51 | 4.53 | ||
| Resistance 2 (R2) | 4.51 | 4.42 | 4.50 | 4.51 | |
| Resistance 1 (R1) | 4.37 | 4.36 | 4.33 | 4.36 | 4.49 |
| Pivot Point | 4.28 | 4.28 | 4.25 | 4.27 | 4.28 |
| Support 1 (S1) | 4.14 | 4.19 | 4.10 | 4.13 | 3.99 |
| Support 2 (S2) | 4.05 | 4.13 | 4.04 | 3.97 | |
| Support 3 (S3) | 3.91 | 4.05 | 3.95 | ||
| Support 4 (S4) | 3.90 |
